217 related articles for article (PubMed ID: 16758263)
1. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
[TBL] [Abstract][Full Text] [Related]
2. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
3. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
Tornio A; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
5. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
6. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.
Karonen T; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2012 Feb; 73(2):257-67. PubMed ID: 21838784
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 May; 63(5):463-9. PubMed ID: 17333159
[TBL] [Abstract][Full Text] [Related]
9. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
10. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
12. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Karonen T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2011 Feb; 67(2):151-5. PubMed ID: 20931329
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
16. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement.
Tayrouz Y; Ganssmann B; Ding R; Klingmann A; Aderjan R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2001 Nov; 70(5):405-14. PubMed ID: 11719726
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
19. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]